Akari Therapeutics Plc — Director's Dealing 2016

Mar 25, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Akari Therapeutics Plc (AKTX)
CIK: 0001541157
Period of Report: 2016-03-23

Reporting Person: SHAW ROBERT M (General Counsel and Secretary)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-03-23	Options to Purchase Ordinary Shares	$14.10	A	1800000	Acquired	2026-03-23	Ordinary Shares (1800000)	Direct

Footnotes

F1: 12.5% of the shares underlying the option will vest on a semi-annual basis over a four year period beginning on 3/23/2016.